Mathematical Modelling of Survival of Glioblastoma Patients Suggests a Role for Radiotherapy Dose Escalation and Predicts Poorer Outcome After Delay to Start Treatment

Using the model, we have extracted biological information from clinical data. The model could be used to assess the potential benefit, or lack of benefit, from a proposed radiotherapy trial, and to estimate the necessary size. It shows that a single modality is unlikely to achieve a major improvement in long-term survival, although radiotherapy dose escalation should have a role, provided it can be given safely. The model could be extended to include chemotherapy, bio-reductive drugs, or gene therapy.